{"id":"W3036655603","doi":"10.1016/j.ahj.2020.06.005","title":"Rationale and design of the RIGHT trial: A multicenter, randomized, double-blind, placebo-controlled trial of anticoagulation prolongation versus no anticoagulation after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction","year":2020,"lang":"en","type":"article","venue":"American Heart Journal","topic":"Acute Myocardial Infarction Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Capital Health Research and Development of Special Fund; Servier; European Society of Cardiology; Amgen; Beijing Municipal Science and Technology Commission; Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support; Japanese Circulation Society; American Heart Association; Natural Science Foundation of Beijing Municipality; China Scholarship Council; National Institute for Health and Care Excellence; Fédération Française de Cardiologie; Daiichi-Sankyo; National Natural Science Foundation of China; Canadian Cardiovascular Society; Idorsia Pharmaceuticals; Capital Medical University; Beijing Municipal Administration of Hospitals; American College of Cardiology Foundation; Pfizer; Sanofi; European Association for Cardio-Thoracic Surgery; Bristol-Myers Squibb; AstraZeneca","keywords":"Medicine; Bivalirudin; Percutaneous coronary intervention; Myocardial infarction; Clinical endpoint; Randomized controlled trial; Internal medicine; Cardiology; Placebo; Surgery","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.03236073,0.005636914,0.007298112,0.001440345,0.002546019,0.00366927,0.002845713,0.006787518,0.01462721],"category_scores_gemma":[0.02924692,0.003337968,0.003191166,0.001189925,0.007969101,0.002904247,0.00124381,0.0079445,0.004060064],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001319517,"about_ca_system_score_gemma":0.005332747,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008740803,"about_ca_topic_score_gemma":0.001385031,"domain_scores_codex":[0.9770542,0.01531457,0.001732258,0.003244558,0.00150168,0.001152791],"domain_scores_gemma":[0.993437,0.002742037,0.001097781,0.0007370597,0.0006586295,0.0013275],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.901475,0.007114183,0.002955139,0.01463074,0.003818581,0.0005883066,0.0006578894,0.002030162,0.004736609,0.01783328,0.01203163,0.03212842],"study_design_scores_gemma":[0.9529989,0.0157766,0.002188691,0.001254155,0.002906579,0.0001682246,0.0000903508,0.001980937,0.0007463836,0.006348806,0.01539432,0.0001459935],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"protocol","genre_gemma":"methods","genre_scores_codex":[0.09247024,0.02765357,0.03249104,0.01377821,0.01781004,0.7973546,0.005909493,0.0009487425,0.01158406],"genre_scores_gemma":[0.1907708,0.005191595,0.04918674,0.01215083,0.004550527,0.7313291,0.0016327,0.000120315,0.005067495],"genre_candidate":"methods","genre_consensus":null,"teacher_disagreement_score":0.03236073,"threshold_uncertainty_score":0.1711419,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04938865742053997,"score_gpt":0.3358609035012863,"score_spread":0.2864722460807463,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}